HPV Vaccine Evidence Pool

We regularly update the content of our evidence base. If you would like to keep up to date, we invite you to subscribe to our updates.

HPV Vaccine Evidence Pool

Introduction

Cervical cancer is the fourth most common cancer in women globally and is the second leading cause of cancer deaths among women aged 15-44 in China. Nearly all cervical cancer cases are caused by human papillomavirus (HPV). Thus, primary prevention of cervical cancer can be effectively achieved through the administration of HPV vaccines. This evidence pool aims to compile and analyze major domestic and international research findings and evidence related to HPV vaccines. It serves as high-quality, evidence-based support for policymakers, media, and other key stakeholders in facilitating advocacy efforts in China to enhance HPV vaccine coverage and promote an increase in vaccination rates.

Establishing this evidence pool and preparing the report received extensive support and assistance from various stakeholders. The project was funded by the Bill and Melinda Gates Foundation and led by the School of Public Health at Peking Union Medical College, with Dr. Luzhao Feng as the principal investigator and Dr. Mengmeng Jia as the project lead. Professor Shenglan Tang’s team at the Duke Global Health Institute, Duke University, provided technical support.

Acknowledgements

We extend our gratitude to Ms. Huijiao Yan, Ms. Sumeng Wang, Ms. Shujun Liu, Ms. Binshan Jiang, and Ms. Mingyang Chen from Peking Union Medical College, as well as Dr. Kelly Hunter, Dr. Emily Herfel, and Mr Lei Guo. from Duke University, for their dedicated efforts during the evidence collection phase.

Dr. Wenfeng Gong and Dr. Heng Du from the Bill and Melinda Gates Foundation, along with Mr. Xu Zhu, project consultant, and Ms Shu Chen from the University of New South Wales, provided substantial support for establishing and improving the evidence repository. Prof. Youlin Qiao from the Peking Union Medical College, Prof. Fanghui Zhao and Dr. Shangying Hu from the National Cancer Center/Cancer Hospital, and Dr. Megan Huchko from Duke University offered invaluable support and insights throughout the project’s execution.